BVZ (Avastin, Genentech) is a humanised anti‐VEGF monoclonal antibody that has been reported to show remarkable effectiveness in suppressing the growth of tumour in different animal models [29] and directly exhibits anti‐vascular effects in colorectal cancers [30]. Here, VEGFA is linked to neoplasm.